Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole

BMC Infectious Diseases

Volumn 7, Issue , 2007, Pages

  Manosuthi, Weerawat ^a   Athichathanabadi, Chatiya ^a   Uttayamakul, Sumonmal ^a   Phoorisri, Thanongsri ^a   Sungkanuparph, Somnuek ^b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FLUCONAZOLE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CRYPTOCOCCOSIS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; LIVER FUNCTION TEST; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MONOTHERAPY; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN NECROSIS; STEVENS JOHNSON SYNDROME; TOXIC HEPATITIS;

ANTI-HIV AGENTS; ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; FLUCONAZOLE; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE; PREGNANCY;

EID: 33947395322     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-7-14     Document Type: Article

References (30)

1. Mitchell TG Perfect JR Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans Clin Microbiol Rev 1995 8 4 515-548 172874 8665468
2. Mirza SA Phelan M Rimland D Graviss E Hamill R Brandt ME Gardner T Sattah M de Leon GP Baughman W Hajjeh RA The changing epidemiology of cryptococcosis: An update from population-based active surveillance in 2 large metropolitan areas, 1992-2000 Clin Infect Dis 2003 36 6 789-794 10.1086/368091 12627365
3. Anekthananon T Ratanasuwan W Techasathit W Rongrungruang Y Suwanagool S HIV infection/acquired immunodeficiency syndrome at Siriraj Hospital, 2002: Time for secondary prevention J Med Assoc Thai 2004 87 2 173-179 15061301
4. Inverarity D Bradshaw Q Wright P Grant A The spectrum of HIV-related disease in rural Central Thailand Southeast Asian J Trop Med Public Health 2002 33 4 822-831 12757233
5. Grant AD Djomand G De Cock KM Natural history and spectrum of disease in adults with HIV/AIDS in Africa Aids 1997 11 Suppl B S43-54 9416366
6. Tansuphasawadikul S Amornkul PN Tanchanpong C Limpakarnjanarat K Kaewkungwal J Likanonsakul S Eampokalap B Naiwatanakul T Kitayaporn D Young NL Hu DJ Mastro TD Clinical presentation of hospitalized adult patients with HIV infection and AIDS in Bangkok, Thailand J Acquir Immune Defic Syndr 1999 21 4 326-332 10428112
7. Saag MS Graybill RJ Larsen RA Pappas PG Perfect JR Powderly WG Sobel JD Dismukes WE Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America Clin Infect Dis 2000 30 4 710-718 10.1086/313757 10770733
8. Stevens DA Management of systemic manifestations of fungal disease in patients with AIDS J Am Acad Dermatol 1994 31 3 Pt 2 S64-7 8077511
9. Kaplan JE Masur H Holmes KK Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America MMWR Recomm Rep 2002 51 RR-8 1-52
10. Vibhagool A Sungkanuparph S Mootsikapun P Chetchotisakd P Tansuphaswaswadikul S Bowonwatanuwong C Ingsathit A Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: A prospective, multicenter, randomized study Clin Infect Dis 2003 36 10 1329-1331 10.1086/374849 12746781
11. Barlett J Gallant J 2005-2006 Medicine Management of HIV infection Baltimore, Johns Hopkins Medicine 2005
12. Gazzard B British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005) HIV Med 2005 6 Suppl 2 1-61 10.1111/j.1468-1293.2005.0311b.x 16011536
13. Bartlett JG The DHHS adult ART guidelines are revised Hopkins HIV Rep 2005 17 1 6-7 16419321
14. Pollard RB Robinson P Dransfield K Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection Clin Ther 1998 20 6 1071-1092 10.1016/ S0149-2918(98)80105-7 9916603
15. Milinkovic A Martinez E Nevirapine in the treatment of HIV Expert Rev Anti Infect Ther 2004 2 3 367-373 10.1586/14787210.2.3.367 15482202
16. Authar RS Sankote J Mahanontharit A Ubolyam S Giel D Cooper D Lange J Phanuphak P Burger D Ruxrungtham K Results from pilot quality control program of generic antiretrovirals: Content and dissolution analysis of generic nevirapine (HIV-NAT026).: 24-27 July 2005; Rio de Janeiro. TUPeB4606 2006, TuPe3.1B02 eiro.
17. Anekthananon T Ratanasuwan W Techasathit W Sonjai A Suwanagool S Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: A 24-week study J Med Assoc Thai 2004 87 7 760-767 15521230
18. Chokephaibulkit K Plipat N Cressey TR Frederix K Phongsamart W Capparelli E Kolladarungkri T Vanprapar N Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine Aids 2005 19 14 1495-1499 10.1097/ 01.aids.0000183625.97170.59 16135903
19. Tin EE Bowonwatanuwong C Desakorn V Wilairatana P Krudsood S Pitisuttithum P The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naive adult HIV patients Southeast Asian J Trop Med Public Health 2005 36 2 362-369 15916042
20. Albengres E Le Louet H Tillement JP Systemic antifungal agents. Drug interactions of clinical significance Drug Saf 1998 18 2 83-97 10.2165/ 00002018-199818020-00001 9512916
21. Kuper JI D'Aprile M Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease Clin Pharmacokinet 2000 39 3 203-214 10.2165/00003088-200039030-00003 11020135
22. Joly V Yeni P [Non-nucleoside reverse transcriptase inhibitors] Ann Med Interne (Paris) 2000 151 4 260-267 10922953
23. Geel J Pitt J Orrell CJ Van Dyk M Wood R The effect of fluconazole on nevirapine pharmacokinetics: July 11-16; Bangkok. 1 369 2004 TuPeB4606
24. Gonzalez de Requena D Nunez M Jimenez-Nacher I Soriano V Liver toxicity caused by nevirapine Aids 2002 16 2 290-291 10.1097/ 00002030-200201250-00020 11807315
25. Manosuthi W Chumpathat N Chaovavanich A Sungkanuparph S Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: A case-control study BMC Infect Dis 2005 5 67 1199598 16120209 10.1186/ 1471-2334-5-67
26. Bradbury BD Jick SS Itraconazole and fluconazole and certain rare, serious adverse events Pharmacotherapy 2002 22 6 697-700 10.1592/ phco.22.9.697.34072 12066960
27. Garcia Rodriguez LA Duque A Castellsague J Perez-Gutthann S Stricker BH A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs Br J Clin Pharmacol 1999 48 6 847-852 10.1046/j.1365-2125.1999.00095.x 10594489
28. Havlir D Cheeseman SH McLaughlin M Murphy R Erice A Spector SA Greenough TC Sullivan JL Hall D Myers M High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection J Infect Dis 1995 171 3 537-545 7533197
29. Kappelhoff BS van Leth F Robinson PA MacGregor TR Baraldi E Montella F Uip DE Thompson MA Russell DB Lange JM Beijnen JH Huitema AD Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther 2005 10 4 489-498 16038474
30. Stern JO Robinson PA Love J Lanes S Imperiale MS Mayers DL A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients J Acquir Immune Defic Syndr 2003 34 Suppl 1 S21-33 14562855